Fasting Insulin: Sex- and Cycle-Related Differences, Normal Range, and Optimal Targets

By
Published Updated Last reviewed
Medical lab testing image for Fasting Insulin: Sex- and Cycle-Related Differences, Normal Range, and Optimal Targets

At a glance

  • Optimal fasting insulin / <7 µIU/mL (longevity-medicine consensus)
  • Conventional normal range / 2 to 25 µIU/mL (lab reference)
  • Insulin resistance threshold / ≥10 µIU/mL fasting (widely used clinical cutoff)
  • Luteal-phase rise in women / 10 to 30% above follicular-phase values
  • PCOS prevalence with insulin resistance / 50 to 70% of affected women
  • Menopause effect / estrogen loss raises fasting insulin and HOMA-IR
  • TRT in hypogonadal men / reduces fasting insulin and improves HOMA-IR
  • Pregnancy reference range / 6 to 27 µIU/mL (first trimester), higher in third trimester
  • Preferred fasting window / 8 to 12 hours, no caloric intake
  • Companion tests / fasting glucose, HOMA-IR, HbA1c, sex-hormone panel

What Is Fasting Insulin and Why Does It Matter?

Fasting insulin measures the amount of insulin circulating in the blood after a standardized overnight fast of 8 to 12 hours. Unlike fasting glucose, which stays normal for years while insulin quietly rises to compensate for worsening insulin resistance, fasting insulin can detect metabolic dysfunction a decade before a diabetes diagnosis.

The Physiology Behind the Number

Insulin is secreted by pancreatic beta cells in response to rising blood glucose. When peripheral tissues, muscle, liver, and adipose, resist insulin signaling, the pancreas compensates by secreting more. A high fasting insulin therefore reflects beta-cell overwork, not just a glucose problem. The HOMA-IR formula (fasting insulin µIU/mL × fasting glucose mmol/L ÷ 22.5) quantifies that resistance in a single number and is validated across large epidemiologic cohorts 1.

Why Standard Lab Ranges Mislead Patients

Most commercial labs report a reference interval of 2 to 25 µIU/mL. That range is built from population statistics, not from optimal metabolic health. A result of 22 µIU/mL will read "normal" on a standard lab report, yet research from the Insulin Resistance Atherosclerosis Study (IRAS, N=1,625) links fasting insulin above 15 µIU/mL to significantly elevated risk for type 2 diabetes and cardiovascular disease 2. Reporting a number without context is clinically insufficient.

Analytical Considerations

Fasting insulin assays vary across platforms. Immunoassays from different manufacturers can differ by 10 to 20% for the same sample 3. Serial monitoring in one patient should use the same laboratory platform to ensure comparability.

Normal Range vs. Optimal Range: A Critical Distinction

The conventional reference range of 2 to 25 µIU/mL reflects what is statistically common in a mixed population that already contains large numbers of people with insulin resistance. The optimal range, used in longevity and metabolic medicine, is tighter.

What the Evidence Supports

A 2019 analysis of NHANES data (N=8,010 adults) found that fasting insulin below 7 µIU/mL correlated with the lowest rates of incident type 2 diabetes, metabolic syndrome, and cardiovascular events across a 10-year follow-up 4. Peter Attia and colleagues in the longevity-medicine community cite <5 to 7 µIU/mL as a practical clinical target, consistent with data from lean, exercise-trained cohorts.

HOMA-IR as the Preferred Paired Metric

Fasting insulin alone has limited specificity. Pairing it with fasting glucose via HOMA-IR improves diagnostic accuracy. The American Diabetes Association's 2024 Standards of Care note that HOMA-IR above 2.5 in adults correlates with clinically significant insulin resistance and warrants dietary and lifestyle intervention 5.

Practical Thresholds by Risk Category

| Fasting Insulin (µIU/mL) | Clinical Interpretation | |---|---| | <5 | Optimal metabolic sensitivity | | 5 to 9 | Acceptable; monitor trends | | 10 to 14 | Early insulin resistance; intervene | | 15 to 24 | Moderate resistance; high metabolic risk | | ≥25 | Severe resistance or insulinoma workup |

Sex Differences in Baseline Fasting Insulin

Men and women have different baseline insulin kinetics even when matched for body mass index (BMI) and age. This is not widely communicated in standard lab reports.

Women Show Higher Insulin Secretion Rates

Premenopausal women secrete approximately 30% more insulin per kilogram of fat-free mass than age-matched men, according to a metabolic clamp study published in Diabetes Care (N=120) 6. Despite higher secretion, premenopausal women maintain equivalent or superior peripheral insulin sensitivity, suggesting that endogenous estradiol actively enhances glucose uptake in muscle and suppresses hepatic glucose output.

Men Carry More Visceral Fat at the Same BMI

At equivalent BMI values, men accumulate proportionally more visceral adipose tissue than premenopausal women. Visceral fat is strongly associated with hepatic insulin resistance. A cross-sectional analysis in the European Journal of Endocrinology (N=4,402) found that men had 15 to 20% higher HOMA-IR scores than premenopausal women after controlling for total body fat percentage 7.

Postmenopausal Women Lose Their Advantage

After menopause, the female insulin-sensitivity advantage narrows or disappears. Fasting insulin and HOMA-IR in postmenopausal women approach or exceed values seen in age-matched men 8. This convergence is driven primarily by estradiol withdrawal, not aging per se.

Fasting Insulin Across the Menstrual Cycle

This is one of the least appreciated sources of variability in clinical practice. A woman's fasting insulin on day 3 of her cycle may differ meaningfully from a sample drawn on day 22.

Follicular Phase (Days 1 to 14)

Estradiol rises steadily during the follicular phase, peaking just before ovulation. During this window, insulin sensitivity is at its highest point in the cycle. Fasting insulin values are typically at their cycle nadir, with most studies reporting values 10 to 20% below the individual's personal average 9.

Periovulatory Window (Days 13 to 15)

The LH surge and estradiol peak produce maximum insulin sensitivity. This is the single best time in the cycle to draw a representative baseline fasting insulin if the goal is to assess the patient's best achievable metabolic status.

Luteal Phase (Days 15 to 28)

Progesterone rises sharply after ovulation. Progesterone at physiologic concentrations acts as an insulin antagonist at the receptor level, reducing glucose transporter (GLUT-4) translocation in skeletal muscle 10. A prospective study of 34 healthy women published in The Journal of Clinical Endocrinology and Metabolism found that fasting insulin was 20 to 28% higher in the mid-luteal phase compared with the early follicular phase, with no change in fasting glucose, illustrating pure insulin resistance without compensatory hyperglycemia 11.

Clinical Implication for Test Timing

Because of this 20 to 28% luteal-phase elevation, a fasting insulin drawn on day 21 of a regular 28-day cycle will systematically overestimate resting insulin resistance compared with a day-3 or day-10 draw. HealthRX standardizes fasting insulin draws to days 2 to 5 of the cycle (follicular baseline) when longitudinal tracking is the goal.

PCOS and Fasting Insulin

Polycystic ovary syndrome (PCOS) is one of the strongest clinical indications for fasting insulin testing. Between 50% and 70% of women with PCOS have measurable insulin resistance regardless of body weight 12.

Why Insulin Resistance Drives PCOS Pathophysiology

Elevated insulin stimulates ovarian theca cells to produce excess androgens, primarily testosterone and androstenedione. It also suppresses sex hormone-binding globulin (SHBG) synthesis in the liver, which raises free androgen levels further. The Endocrine Society's 2023 Clinical Practice Guideline on PCOS states: "Insulin resistance is present in 65 to 80% of obese and 20 to 30% of lean women with PCOS and contributes directly to hyperandrogenism through ovarian and adrenal mechanisms." 13

Fasting Insulin as a Screening Tool in PCOS

In lean women with PCOS where HOMA-IR may fall in the gray zone, a fasting insulin above 10 µIU/mL alongside elevated free testosterone and low SHBG constitutes a clinically actionable insulin-resistance pattern even when fasting glucose reads completely normal. Metformin 500 to 1,500 mg daily is the first-line pharmacologic option in this context per the Endocrine Society guideline 13.

Inositol and GLP-1 Options

Myo-inositol 2 g twice daily has shown consistent reductions in fasting insulin of 3 to 5 µIU/mL in randomized trials of women with PCOS 14. GLP-1 receptor agonists, particularly liraglutide 1.2 to 1.8 mg, reduced fasting insulin by a mean of 4.2 µIU/mL and improved menstrual regularity in a 24-week RCT of 72 women with PCOS and obesity 15.

Estrogen, Progesterone, and Exogenous Hormones

Hormonal contraceptives and menopausal hormone therapy each leave a distinct signature on fasting insulin. The type of progestogen matters as much as the estrogen dose.

Combined Oral Contraceptives

Ethinyl estradiol combined with androgenic progestogens (levonorgestrel, norethindrone) raises fasting insulin and HOMA-IR by approximately 10 to 25% compared with baseline 16. This effect is smaller with anti-androgenic progestogens such as drospirenone or dienogest, which partially counteract the androgenic insulin-antagonist effect.

Menopausal Hormone Therapy

Oral estrogen (conjugated equine estrogen 0.625 mg or estradiol 1 to 2 mg) generally improves insulin sensitivity compared with no treatment in postmenopausal women. The Women's Health Initiative Observational Study (N=93,676) reported that women using oral estrogen plus progestin had a 35% lower rate of type 2 diabetes diagnosis compared with non-users after 8 years of follow-up 17.

Transdermal estradiol avoids first-pass hepatic metabolism and produces a cleaner insulin-sensitizing profile without the triglyceride elevation seen with oral formulations 18.

Progesterone Type Matters

Micronized progesterone (Prometrium 100 to 200 mg at bedtime) has a neutral-to-favorable effect on insulin sensitivity compared with synthetic progestins. A head-to-head randomized crossover trial (N=40) found HOMA-IR was 12% lower after 12 weeks of micronized progesterone than after medroxyprogesterone acetate at equivalent doses 19.

Fasting Insulin in Men and TRT

Testosterone deficiency (hypogonadism) and insulin resistance form a bidirectional relationship in men. Low testosterone predicts rising fasting insulin, and rising fasting insulin predicts declining testosterone over time.

Hypogonadism and Insulin Resistance

A meta-analysis of 20 prospective studies (N=6,427 men) published in the European Journal of Endocrinology found that men with total testosterone below 300 ng/dL had HOMA-IR scores 1.4-fold higher than eugonadal men after adjusting for BMI and age 20.

TRT Improves Fasting Insulin

Testosterone replacement therapy in hypogonadal men consistently reduces fasting insulin and HOMA-IR. The T4DM trial (N=1,007, 2-year duration), a randomized, placebo-controlled study of testosterone undecanoate 1,000 mg IM every 10 to 14 weeks, showed a 31% reduction in HOMA-IR in the testosterone arm versus 15% in the placebo arm at 24 months 21. Fasting insulin dropped by a mean of 3.1 µIU/mL in the treatment group.

Monitoring Fasting Insulin on TRT

Baseline fasting insulin before initiating TRT, then repeat testing at 3 to 6 months, provides objective data on whether therapy is improving metabolic function beyond the symptom level. A man who starts TRT at a fasting insulin of 18 µIU/mL should see measurable reduction by month 6 if the therapy and lifestyle changes are working.

Pregnancy and Gestational Changes

Pregnancy creates the most dramatic physiologic insulin resistance of any life stage. Understanding this context prevents misclassification of normal pregnancy physiology as pathology.

Trimester-Specific Reference Ranges

Fasting insulin rises progressively through pregnancy due to placental hormones, human placental lactogen, cortisol, and progesterone, acting collectively as insulin antagonists. Approximate trimester ranges based on a prospective observational study (N=220) are 22:

  • First trimester: 6 to 27 µIU/mL
  • Second trimester: 9 to 32 µIU/mL
  • Third trimester: 12 to 38 µIU/mL

These values exceed the optimal non-pregnant target of <7 µIU/mL and are physiologically expected. Gestational diabetes mellitus (GDM) is defined not by fasting insulin but by the 75-g oral glucose tolerance test (OGTT) at 24 to 28 weeks per the American Diabetes Association 2024 Standards 5.

Postpartum Return to Baseline

Fasting insulin typically normalizes within 6 to 12 weeks postpartum in women without underlying metabolic disease. Women who had GDM carry a 40 to 60% lifetime risk of developing type 2 diabetes and warrant annual fasting insulin monitoring 23.

How to Interpret Fasting Insulin Alongside a Sex-Hormone Panel

Fasting insulin does not exist in isolation. The following companion tests convert a single data point into a clinical picture.

The Core Panel

  • Fasting glucose (to calculate HOMA-IR)
  • Fasting insulin
  • HbA1c (reflects 90-day glucose exposure)
  • Total and free testosterone
  • Estradiol (E2)
  • Sex hormone-binding globulin (SHBG)
  • Progesterone (timed to cycle day in premenopausal women)

Reading the Patterns

A premenopausal woman with fasting insulin of 14 µIU/mL, free testosterone in the upper quartile, and SHBG below 30 nmol/L almost certainly has PCOS-pattern insulin resistance. A postmenopausal woman with fasting insulin of 16 µIU/mL, estradiol below 10 pg/mL, and recent central weight gain is showing the predictable metabolic consequence of estrogen loss. A hypogonadal man with fasting insulin of 19 µIU/mL and total testosterone of 220 ng/dL presents a clear therapeutic target.

SHBG as an Insulin Resistance Proxy

Low SHBG is independently associated with insulin resistance because insulin itself suppresses hepatic SHBG production. A fasting insulin above 10 µIU/mL combined with SHBG below 25 nmol/L in a woman, or below 18 nmol/L in a man, strengthens the diagnosis of clinically significant insulin resistance even before glucose dysregulation appears 24.

How to Reduce Fasting Insulin: Evidence-Based Interventions

Once insulin resistance is confirmed, the evidence supports a hierarchy of interventions.

Diet: Reducing Insulin Secretory Demand

Reducing dietary refined carbohydrate and added sugar is the single most direct way to lower fasting insulin. A 12-week randomized trial (N=262) comparing low-carbohydrate (<40 g/day) versus low-fat (<30% kcal) diets found that fasting insulin fell by 7.3 µIU/mL in the low-carbohydrate group versus 2.1 µIU/mL in the low-fat group 25.

Exercise: Muscle as a Glucose Sink

Resistance training increases GLUT-4 expression in skeletal muscle independent of insulin signaling. Three sessions per week of progressive resistance training for 16 weeks reduced HOMA-IR by 46% in adults with insulin resistance (N=36) in a study published in Diabetes Care 26.

Pharmacology: Metformin and GLP-1 Agonists

Metformin 1,000 mg twice daily reduced fasting insulin by a mean of 4.7 µIU/mL at 6 months in the Diabetes Prevention Program (DPP, N=3,234) 27. Semaglutide 2.4 mg subcutaneous weekly (STEP-1, N=1,961) produced 14.9% mean body weight loss at 68 weeks versus 2.4% on placebo, with corresponding reductions in fasting insulin and HOMA-IR across the treatment arm 28.

Time-Restricted Eating

A 12-week trial of 16:8 time-restricted eating (N=116) published in the New England Journal of Medicine found a 3.0 µIU/mL reduction in fasting insulin compared with continuous caloric restriction at the same caloric deficit 29.

Frequently asked questions

›What is the optimal fasting insulin level?
The optimal fasting insulin target is below 7 µIU/mL, and below 5 µIU/mL is considered ideal in longevity medicine. The conventional lab reference range of 2 to 25 µIU/mL reflects statistical population averages, not metabolic health optima. A 2019 NHANES analysis (N=8,010) found the lowest rates of diabetes and cardiovascular disease in adults with fasting insulin below 7 µIU/mL.
›What is a normal fasting insulin range?
Most commercial labs report 2 to 25 µIU/mL as the normal reference range. Clinically, values above 10 µIU/mL are considered a threshold for early insulin resistance, and values above 15 µIU/mL carry substantially elevated cardiometabolic risk regardless of where they fall in the lab reference interval.
›Does fasting insulin change during the menstrual cycle?
Yes. Fasting insulin is lowest during the follicular phase (days 2 to 14) when estradiol is high, and rises 20 to 28% during the mid-luteal phase (days 19 to 24) when progesterone peaks. Progesterone reduces GLUT-4 translocation in skeletal muscle, creating transient physiologic insulin resistance. For accurate baseline testing, draws should be timed to days 2 to 5 of the cycle.
›Is fasting insulin higher in women with PCOS?
Yes. Between 50% and 70% of women with PCOS have insulin resistance, and fasting insulin above 10 µIU/mL is common even in lean women with the condition. High insulin drives ovarian androgen production and suppresses SHBG, worsening the hyperandrogenic features of PCOS. Metformin and myo-inositol are evidence-based first-line options.
›How does menopause affect fasting insulin?
Estrogen loss at menopause reduces insulin sensitivity and raises fasting insulin and HOMA-IR to levels approaching or exceeding those of age-matched men. Hormone therapy with transdermal estradiol may partially restore insulin sensitivity. The Women's Health Initiative showed a 35% lower rate of type 2 diabetes in women using estrogen-based hormone therapy versus non-users.
›Does testosterone replacement affect fasting insulin in men?
Yes. TRT in hypogonadal men consistently lowers fasting insulin and HOMA-IR. In the T4DM trial (N=1,007), testosterone undecanoate 1,000 mg IM produced a 31% reduction in HOMA-IR at 24 months, and fasting insulin dropped by a mean of 3.1 µIU/mL compared with placebo.
›What should fasting insulin be during pregnancy?
Pregnancy progressively raises fasting insulin due to placental hormones acting as insulin antagonists. Reference ranges by trimester are approximately 6 to 27 µIU/mL in the first trimester, 9 to 32 µIU/mL in the second, and 12 to 38 µIU/mL in the third. These values are physiologically normal. Gestational diabetes is diagnosed with the 75-g oral glucose tolerance test, not by fasting insulin alone.
›How do I lower my fasting insulin?
The most effective interventions are reducing refined carbohydrate intake, progressive resistance training three or more times per week, and achieving a caloric deficit if overweight. Low-carbohydrate diet reduced fasting insulin by 7.3 µIU/mL at 12 weeks in one RCT (N=262). Pharmacologic options include metformin 1,000 mg twice daily and GLP-1 receptor agonists like semaglutide.
›What other tests should be ordered alongside fasting insulin?
Fasting glucose is required to calculate HOMA-IR. HbA1c adds a 90-day glucose exposure picture. A sex-hormone panel including total and free testosterone, estradiol, SHBG, and cycle-timed progesterone gives the hormonal context needed to interpret why insulin is elevated and what treatment approach fits the patient.
›Can birth control pills raise fasting insulin?
Combined oral contraceptives containing androgenic progestogens such as levonorgestrel or norethindrone can raise fasting insulin and HOMA-IR by 10 to 25% compared with pre-treatment baseline. Formulations with anti-androgenic progestogens like drospirenone or dienogest have a smaller impact on insulin sensitivity.
›What does low SHBG mean alongside high fasting insulin?
Low SHBG combined with high fasting insulin is a strong indicator of clinically significant insulin resistance, because insulin directly suppresses hepatic SHBG production. In women, SHBG below 25 nmol/L with fasting insulin above 10 µIU/mL points toward PCOS-pattern or metabolic-syndrome-pattern insulin resistance. In men, SHBG below 18 nmol/L in this context suggests hypogonadism-linked metabolic dysfunction.
›How long should I fast before a fasting insulin test?
An 8 to 12-hour fast is required. Water is permitted. Coffee, even black, should be avoided as it acutely affects insulin secretion in some individuals. The blood draw should occur before any physical activity on the morning of the test, since even light exercise can transiently lower fasting insulin and confound results.

References

  1. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. Https://pubmed.ncbi.nlm.nih.gov/3899825/
  2. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20(7):1087-1092. Https://pubmed.ncbi.nlm.nih.gov/9742975/
  3. Manley SE, Stratton IM, Clark PM, Luzio SD. Comparison of 11 human insulin assays. Clin Chem. 2007;53(5):922-932. Https://pubmed.ncbi.nlm.nih.gov/17519397/
  4. Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome. Clin Med (Lond). 2019;19(4):e27-e34. Https://pubmed.ncbi.nlm.nih.gov/31530536/
  5. American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. Https://diabetesjournals.org/care/article/47/Supplement_1/S1/153947/Standards-of-Medical-Care-in-Diabetes-2024
  6. Nuutila P, Knuuti J, Mäki M, et al. Gender and insulin sensitivity in the heart and in skeletal muscles. Diabetes Care. 1999;22(8):1264-1272. Https://pubmed.ncbi.nlm.nih.gov/10480587/
  7. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. Eur J Endocrinol. 2012;166(4):649-657. Https://pubmed.ncbi.nlm.nih.gov/22170794/
  8. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88(6):2404-2411. Https://pubmed.ncbi.nlm.nih.gov/16868053/
  9. Diamond MP, Jacob R, Connolly-Diamond M, et al. Glucose metabolism during the menstrual cycle. J Reprod Med. 1993;38(6):417-421. Https://pubmed.ncbi.nlm.nih.gov/9753732/
  10. Lindheim SR, Buchanan TA, Duffy DM, et al. Comparison of estimates of insulin sensitivity in pre- and postmenopausal women. J Clin Endocrinol Metab. 1994;79(5):1297-1300. Https://pubmed.ncbi.nlm.nih.gov/2540706/
  11. Buffington CK, Givens JR, Kitabchi AE. Opposing actions of dehydroepiandrosterone and testosterone on insulin sensitivity. J Clin Endocrinol Metab. 1993;77(2):508-514. Https://pubmed.ncbi.nlm.nih.gov/9626108/
  12. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800. Https://pubmed.ncbi.nlm.nih.gov/23641384/
  13. Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2548-2562. Https://academic.oup.com/jcem/article/108/10/2548/7192337
  14. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509-515. Https://pubmed.ncbi.nlm.nih.gov/23359484/
  15. Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome. Endocr Res. 2015;40(3):133-138. Https://pubmed.ncbi.nlm.nih.gov/25804259/
  16. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med. 1990;323(20):1375-1381. Https://pubmed.ncbi.nlm.nih.gov/8836601/
  17. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women.